The National Agency for Food and Drugs Administration and Control (NAFDAC) has put on alert the flow of Augmentin 625mg Tabs that are suspected to be fake in the country. According to the agency, the products are suspectedly fake as a result of failure to meet labeling requirements.
This was communicated in a statement signed by the management of NAFDAC which was titled; NAFDAC Alert And Sensitization Of The Public On Suspected Falsified Augmentin 625mg’. NAFDAC said the suspected product which was produced April 2021 will expire in April 2024.
It also pointed out that the batch number of the fake drug is 562626 with a NAFDAC registration number- 04-1928. NAFADAC said “The product failed short of the labeling requirements. No inscription “manufactured by” is written on the label -only the address.
“Manufacturing and Expiry dates do not meet the acceptable format. No MAS scratch number for verification. “The logo “gsk” is not properly positioned as on the original. The listed information indicates the product is falsified and counterfeited. “In view of the above, NAFDAC has notified all its formations in the zones and 36 states of the federation including the FCT to carry out surveillance and mop up the falsified Augmentin tablets.”
“Please note that the genuine Augmentin 625mg has legible product labeling information including date markings – expiration and manufactured dates, batch number and NAFDAC registration number.
READ ALSO: Tambuwal Alleges That APC Owns A Fake News Factory
“NAFDAC advise to wholesalers, distributors, and pharmacies is that medicines should be obtained from authorized/licensed suppliers, increased vigilance is hereby encouraged within the supply chain to avoid infiltration of the falsified product. The products’ authenticity, physical condition and labels should be carefully checked.
“NAFDAC implores healthcare providers to ensure vigilance to prevent the administration of falsified products to unsuspecting patients. Members of the public in possession of the above suspected counterfeit product are advised to discontinue sale or use and submit stock to the nearest NAFDAC office.
“Healthcare providers and the public should notify the nearest NAFDAC office of any information concerning the distribution, sale, and use of the falsified version of the Augmentin product. Report any suspicion of adverse drug reaction and substandard and falsified medicines to NAFDAC on 0800-162-3322 or email:
sf.alert@nafdac.gov.ng.”
